Skip to main content
Top
Published in: Internal and Emergency Medicine 8/2014

01-12-2014 | IM - ORIGINAL

Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry

Authors: Chiara Piovella, Fabio Dalla Valle, Javier Trujillo-Santos, Raffaele Pesavento, Leonor López, Llorenç Font, Reina Valle, Dolores Nauffal, Manuel Monreal, Paolo Prandoni, And the RIETE Investigators

Published in: Internal and Emergency Medicine | Issue 8/2014

Login to get access

Abstract

Stratification of the individual bleeding risk prior to initiation of anticoagulation in patients with acute venous thromboembolism (VTE) has the potential to assist clinicians in making decisions about the proper intensity and duration of antithrombotic therapy. It is unclear which of the validated and internationally accepted scores recommended for the achievement of this important task has the best predictive value. We compared the predictive value of four validated scores (by Landefeld, Beyth, Kuijer and Ruiz-Gimenez, respectively) for the development of major bleeding complications occurring in the first 3 months in patients with acute VTE treated with conventional anticoagulation. Based on the population of RIETE Registry (international registry of patients with acute VTE), we identified those patients presenting all the required prognostic variables, and then calculated the ability of each score for predicting the bleeding risk. Of 40,265 eligible patients, we identified 8,717 meeting the recruitment criteria. Overall, 0.9 % of patients experienced at least one episode of major bleeding within 90 days of the index event. The proportion of patients classified as having a low risk varied between 1.2 and 3.7 %, that of patients having an intermediate risk between 76 and 93 %, and that of patients classified as having a high risk between 6.1 and 18 %. The area under the receiver operating characteristic ranged between 0.55 and 0.60, the positive predictive value between 1.5 and 3.2, and the likelihood ratio between 0.72 and 1.59. In conclusion, all four scores show a very low ability to predict the bleeding risk in patients with acute VTE undergoing conventional anticoagulation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 108(suppl 4):231–246SCrossRef Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 108(suppl 4):231–246SCrossRef
2.
go back to reference Ageno W (2012) Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism? Intern Emerg Med 7(Suppl 3):189–192CrossRef Ageno W (2012) Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism? Intern Emerg Med 7(Suppl 3):189–192CrossRef
3.
go back to reference Ageno W, Agnelli G, Imberti D et al (2013) Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. Intern Emerg Med 8:575–580PubMedCrossRef Ageno W, Agnelli G, Imberti D et al (2013) Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. Intern Emerg Med 8:575–580PubMedCrossRef
4.
go back to reference Imberti D, Bianchi C, Zambon A et al (2012) Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 7:243–249PubMedCrossRef Imberti D, Bianchi C, Zambon A et al (2012) Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 7:243–249PubMedCrossRef
5.
go back to reference Gavish I, Brenner B (2011) Air travel and the risk of thromboembolism. Intern Emerg Med 6:113–116PubMedCrossRef Gavish I, Brenner B (2011) Air travel and the risk of thromboembolism. Intern Emerg Med 6:113–116PubMedCrossRef
6.
go back to reference Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315–328PubMedCrossRef Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315–328PubMedCrossRef
7.
go back to reference Van der Meer FJM, Rosendaal FR, Vandenbroucke W, Briet E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76:12–16PubMed Van der Meer FJM, Rosendaal FR, Vandenbroucke W, Briet E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76:12–16PubMed
8.
go back to reference Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428PubMedCrossRef Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428PubMedCrossRef
9.
go back to reference Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:257–298SCrossRef Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:257–298SCrossRef
10.
go back to reference Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47:565–594PubMedCrossRef Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47:565–594PubMedCrossRef
11.
go back to reference Arcelus JI, Monreal M, Caprini JA et al (2008) Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb Haemost 99:546–551PubMed Arcelus JI, Monreal M, Caprini JA et al (2008) Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb Haemost 99:546–551PubMed
12.
go back to reference Munoz FJ, Mismetti P, Poggio R et al (2008) Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 133:143–148PubMedCrossRef Munoz FJ, Mismetti P, Poggio R et al (2008) Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 133:143–148PubMedCrossRef
13.
go back to reference Trujillo-Santos J, Prandoni P et al (2008) Clinical outcome in patients with venous thromboembolism and hidden cancer. Findings from the RIETE Registry. J Thromb Haemost 6:251–255PubMedCrossRef Trujillo-Santos J, Prandoni P et al (2008) Clinical outcome in patients with venous thromboembolism and hidden cancer. Findings from the RIETE Registry. J Thromb Haemost 6:251–255PubMedCrossRef
14.
go back to reference Laporte S, Mismetti P, Decousus H et al (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism; Findings from the registro informatizado de la enfermedad tromboembolica venosa (RIETE) Registry. Circulation 117:1711–1716PubMedCrossRef Laporte S, Mismetti P, Decousus H et al (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism; Findings from the registro informatizado de la enfermedad tromboembolica venosa (RIETE) Registry. Circulation 117:1711–1716PubMedCrossRef
15.
go back to reference Landefeld CS, Goldman L (1989) Major bleeding in out-patients treated with warfarin:incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144–152PubMedCrossRef Landefeld CS, Goldman L (1989) Major bleeding in out-patients treated with warfarin:incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144–152PubMedCrossRef
16.
go back to reference Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91–99PubMedCrossRef Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91–99PubMedCrossRef
17.
go back to reference Kuijer PM, Hutten BA, Prins MH, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460PubMedCrossRef Kuijer PM, Hutten BA, Prins MH, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460PubMedCrossRef
18.
go back to reference Ruiz-Gimenez N, Suarez C, Gonzalez R et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26–31PubMed Ruiz-Gimenez N, Suarez C, Gonzalez R et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26–31PubMed
19.
go back to reference Scherz N, Méan M, Limacher A et al (2013) Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost 11:435–443PubMedCrossRef Scherz N, Méan M, Limacher A et al (2013) Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost 11:435–443PubMedCrossRef
20.
go back to reference Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125:1095–1102PubMedCrossRef Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125:1095–1102PubMedCrossRef
21.
go back to reference Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease. In: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):419–494 Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease. In: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):419–494
22.
go back to reference Prandoni P, Prins MH, Lensing AWA et al (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150:577–585PubMedCrossRef Prandoni P, Prins MH, Lensing AWA et al (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150:577–585PubMedCrossRef
23.
go back to reference Palareti G, Cosmi B, Legnani C et al (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355:1780–1789PubMedCrossRef Palareti G, Cosmi B, Legnani C et al (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355:1780–1789PubMedCrossRef
24.
go back to reference Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism; a management study. Blood 2014 [epub ahead of print] Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism; a management study. Blood 2014 [epub ahead of print]
25.
go back to reference Wells PS, Forgie MA, Simms M et al (2003) The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163:917–920PubMedCrossRef Wells PS, Forgie MA, Simms M et al (2003) The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163:917–920PubMedCrossRef
26.
go back to reference Aspinall SL, DeSanzo BE, Trilli LE et al (2005) Bleeding risk index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med 20:1008–1013PubMedCentralPubMedCrossRef Aspinall SL, DeSanzo BE, Trilli LE et al (2005) Bleeding risk index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med 20:1008–1013PubMedCentralPubMedCrossRef
Metadata
Title
Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry
Authors
Chiara Piovella
Fabio Dalla Valle
Javier Trujillo-Santos
Raffaele Pesavento
Leonor López
Llorenç Font
Reina Valle
Dolores Nauffal
Manuel Monreal
Paolo Prandoni
And the RIETE Investigators
Publication date
01-12-2014
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 8/2014
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-014-1073-8

Other articles of this Issue 8/2014

Internal and Emergency Medicine 8/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.